Abstract: The present disclosure provides platinum-containing conjugates that selectively target and kill tumor/cancer cells. The conjugates contain a moiety that selectively targets COX-2, which is overexpressed by a broad range of tumor/cancer cells.
Type:
Grant
Filed:
December 18, 2015
Date of Patent:
August 21, 2018
Assignee:
REILEY PHARMACEUTICALS, INC.
Inventors:
Mark A. Reiley, B. Michael Silber, Xiaoqi Chen
Abstract: Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections.
Type:
Grant
Filed:
June 22, 2015
Date of Patent:
December 26, 2017
Assignee:
Reiley Pharmaceuticals, Inc.
Inventors:
Mark A. Reiley, B. Michael Silber, Julio Medina, Frank Kayser, William D. Shrader